olivLaw · US equity research
Savara Inc SVRA
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, whose sole candidate MOLBREEVI targets autoimmune PAP. The FDA review was extended to November 22, 2026, which makes the approval timeline central for the company. The company has no product revenue and relies on equity offerings and loans to fund losses.
At the close of 04 Nov 2026, Savara Inc (SVRA) stock was 4.66 USD (−1.89% on the day), with market capitalisation 957.4 m USD, beta 1.04, 52-week range 3.95–6.94 USD. Latest reported quarter (Q2 2026): net income of -40.2 m USD, diluted EPS -0.16 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 45.3
- neutral
- Bollinger (20, 2)
- 4.36 – 5.08
- in the lower half of the band · %B 0.41 · band width 15.3%
- SMA 50 / 200
- 5.02 / 5.37
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.07 / -0.10
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −2.5% | −1.1% | −1.4 pp | — |
| 3 months | −15.4% | −0.5% | −15.0 pp | — |
| 6 months | −11.6% | +4.4% | −16.0 pp | — |
| Year to date | −22.7% | +12.3% | −35.0 pp | — |
| 1 year | +12.8% | +13.5% | −0.7 pp | +8.9% |
| 3 years | +23.0% | +76.4% | −53.5 pp | +15.7% |
| 5 years | +288.3% | +63.7% | +224.7 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -26.4 m | -31.2 m | -28.4 m | -31.4 m | -30.3 m | -33.4 m | -39.0 m | -41.0 m |
| Depreciation & amortisation | 33.0 k | 32.0 k | 30.0 k | 34.0 k | 36.0 k | -11.0 k | 24.0 k | 28.0 k |
| Pre-tax income | — | — | -26.6 m | — | — | — | — | — |
| Net income | -24.2 m | -29.0 m | -26.6 m | -30.4 m | -29.6 m | -32.2 m | -37.3 m | -40.2 m |
| Diluted EPS | -0.11 | -0.13 ≈ | -0.12 | -0.14 | -0.14 | -0.13 ≈ | -0.15 | -0.16 |
| Operating cash flow | -22.7 m ≈ | -23.3 m | -27.2 m | -26.3 m ≈ | -22.5 m ≈ | -25.1 m | -33.0 m | -29.7 m ≈ |
| Capex | 3.0 k ≈ | -9.0 k | 3.0 k | 15.0 k ≈ | 2.0 k ≈ | 2.0 k | 54.0 k | 222.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | 0 | 257.0 k | unavailable | unavailable | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -61.5 m | -78.2 m | -49.6 m | -43.0 m | -38.2 m | -54.7 m | -95.9 m | -118.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | -0.32 | -0.25 | -0.33 | -0.48 | -0.53 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | -19,305.4% | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | -39.4 m | -45.3 m | -39.9 m | -40.1 m | -34.6 m | -51.4 m | -89.1 m | -101.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 33.2 m USD
- Financial debt
- 29.9 m USD
- Net debt
- -3.3 m USD
- Equity
- -87.0 k USD
- Total assets
- 253.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 11.85x
- ROE
- unavailable
- ROA
- -51.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 257.0 k | — | — | — | — | — | SEC (XBRL)· 10 Mar 2021verified |
| Operating income | -49.3 m | -41.5 m | -38.8 m | -60.0 m | -103.2 m | -123.5 m | SEC (XBRL)· 13 Mar 2026verified |
| Depreciation & amortisation | 255.0 k | 136.0 k | 31.0 k | 77.0 k | 130.0 k | 87.0 k | SEC (XBRL)· 13 Mar 2026verified |
| EBITDA | -49.0 m ≈ | -41.3 m ≈ | -38.8 m ≈ | -59.9 m ≈ | -103.1 m ≈ | -123.5 m ≈ | SEC (XBRL)· 13 Mar 2026derived |
| Pre-tax income | -49.6 m | -43.0 m | -38.2 m | -54.7 m | -95.9 m | -118.8 m | SEC (XBRL)· 13 Mar 2026verified |
| Income tax | — | — | — | — | 9.0 k | 0 | SEC (XBRL)· 13 Mar 2026verified |
| Net income | -49.6 m | -43.0 m | -38.2 m | -54.7 m | -95.9 m | -118.8 m | SEC (XBRL)· 13 Mar 2026verified |
| Diluted EPS | — | -0.32 | -0.25 | -0.33 | -0.48 | -0.53 | SEC (XBRL)· 13 Mar 2026verified |
| Weighted average diluted shares | — | 133.9 m | 152.8 m | 165.2 m | 198.2 m | 222.4 m | SEC (XBRL)· 13 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 22.9 m | 34.0 m | 52.1 m | 26.6 m | 15.1 m | 33.2 m | SEC (XBRL)· 13 Mar 2026verified |
| Current assets | 85.1 m | 165.0 m | 129.0 m | 165.9 m | 202.1 m | 241.6 m | SEC (XBRL)· 13 Mar 2026verified |
| Property, plant & equipment, net | 156.0 k | 73.0 k | 51.0 k | 270.0 k | 165.0 k | 100.0 k | SEC (XBRL)· 13 Mar 2026verified |
| Goodwill | 0 | — | — | — | — | — | SEC (XBRL)· 10 Mar 2021verified |
| Total assets | 97.7 m | 176.6 m | 139.8 m | 177.6 m | 212.9 m | 253.4 m | SEC (XBRL)· 13 Mar 2026verified |
| Accounts payable | 2.6 m | 1.4 m | 1.3 m | 3.5 m | 4.5 m | 5.8 m | SEC (XBRL)· 13 Mar 2026verified |
| Short-term debt | — | 8.3 m | — | — | 0 | 0 | SEC (XBRL)· 13 Mar 2026verified |
| Long-term debt | 25.1 m | 17.3 m | 26.1 m | 26.3 m | 26.6 m | 29.9 m | SEC (XBRL)· 13 Mar 2026verified |
| Current liabilities | 8.2 m | 14.7 m | 5.9 m | 10.6 m | 14.7 m | 20.4 m | SEC (XBRL)· 13 Mar 2026verified |
| Total liabilities | 33.4 m | 32.1 m | 32.0 m | 37.2 m | 41.4 m | 50.3 m | SEC (XBRL)· 13 Mar 2026verified |
| Equity | 942.0 k | 5.0 k | -605.0 k | -271.0 k | -750.0 k | -87.0 k | SEC (XBRL)· 13 Mar 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -39.8 m | -40.1 m | -34.6 m | -51.1 m | -89.1 m | -101.0 m | SEC (XBRL)· 13 Mar 2026verified |
| Capex | 47.0 k | 57.0 k | 9.0 k | 296.0 k | 25.0 k | 22.0 k | SEC (XBRL)· 13 Mar 2026verified |
| Free cash flow | -39.9 m ≈ | -40.1 m ≈ | -34.6 m ≈ | -51.4 m ≈ | -89.1 m ≈ | -101.1 m ≈ | SEC (XBRL)· 13 Mar 2026derived |
| Investing cash flow | 9.1 m | -69.5 m | 52.6 m | -57.1 m | -39.9 m | -18.4 m | SEC (XBRL)· 13 Mar 2026verified |
| Financing cash flow | 3.7 m | 120.8 m | 87.0 k | 82.8 m | 117.6 m | 137.8 m | SEC (XBRL)· 13 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 957.4 m USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 10.1x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -11.6% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Savara Inc (SVRA). Latest full fiscal year: 2020; data up to 2026-06-30.
Figures computed from the financial statements: revenue 257.0 k USD in 2020; ROE -105.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 10.1x
What contradicts it
- FCF yield: -11.6%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| HRMYHarmony Biosciences Holdings, Inc. | 2.0 bn | 11.4 | 18.7% | 18.1% | +21.5% | −2% / +18% |
| OMEROmeros Corp | 1.3 bn | 10.5 | — | — | −34.0% | +88% / +730% |
| SVRASavara Inc | 957.4 m | — | -105.5% | — | unavailable | +13% / +23% |
| VSTMVerastem, Inc. | 892.0 m | — | -471.2% | -231.6% | +209.1% | −7% / +43% |
| COLLCollegium Pharmaceutical, Inc. | 770.6 m | 19.1 | 17.6% | 5.9% | +23.6% | −49% / −8% |
| IBOImpact BioMedical, INC. | 442.1 m | 560.3 | 371.3% | 2,254.3% | unavailable | −27% / unavailable |
| KMDAKamada Ltd | 428.0 m | 21.2 | 7.6% | 11.2% | +12.1% | +11% / +57% |
1- and 3-year price returns: for SVRA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, whose sole candidate MOLBREEVI targets autoimmune PAP. The FDA review was extended to November 22, 2026, which makes the approval timeline central for the company 2. The company has no product revenue and relies on equity offerings and loans to fund losses 12.
SWOT
Strengths
- The company has a single advanced program with a pivotal Phase 3 study, FDA Fast Track and Breakthrough Therapy designations, and exclusive access to the eFlow device for this indication 1.
- The application already has Priority Review in the U.S., and marketing applications are validated in Europe and the UK 2.
- The outsourcing model reduces fixed costs and allows relatively capital-efficient development 1.
Weaknesses
- The company has no product revenue and records recurring net losses, making it dependent on external funding 12.
- Cash available is limited relative to planned spending, and the company acknowledges it will need additional capital 2.
- The application was initially refused for filing, and manufacturing comparability between suppliers required further clarification 12.
Opportunities
Risks
- Dependence on a single producthigh
The company depends almost entirely on the clinical and regulatory success of MOLBREEVI, so a failure would affect the entire portfolio 1.
- Regulatory timelinehigh
The FDA decision date has been extended and the application was already refused once, showing a further delay is possible 12.
- Capital requirementshigh
The company will need additional funds for development and launch, and financing terms may be less favorable 12.
- Manufacturing and supply chainmedium
Production depends on external suppliers, and any quality or technology transfer problem could delay supply 1.
- Litigation and investor attentionlow
A securities class action and a derivative action were filed in 2025 and later dismissed without prejudice, but could be reopened 1.
Investment thesis
What would need to be true (bull case)
- If the FDA approves MOLBREEVI, the company could become the first approved treatment for autoimmune PAP, with market exclusivity and a royalty payment linked to approval 1.
- IMPALA-2 data show significant improvements in DLCO and quality of life scores, with very high trial completion 1.
- Validation of marketing applications in Europe and the UK could expand commercial potential if regulators confirm clinical benefit 2.
What would break the thesis
- The autoimmune PAP market is very small, and commercial success could remain limited even after approval 1.
- The company has no revenue and depends on external capital, which could force dilution or less favorable financing terms 12.
- The initial refusal and the extended review show regulators can request clarifications, and approval is not assured 12.
What to watch
- FDA decision on the MOLBREEVI BLANovember 2026
- CHMP opinion from the EMA on the marketing application2026
- Cash position and need for additional capitalnext quarterly report
- Possible Hercules loan tranches after approval2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Savara Inc. develops molgramostim inhalation, branded MOLBREEVI, an inhaled form of recombinant human GM-CSF for autoimmune PAP, a rare lung disease 1. The product is a drug-device combination, administered once daily with the eFlow nebulizer from PARI Pharma 1. The company outsources manufacturing and most clinical operations and has no product revenue to date 1.
The main clinical evidence is the Phase 3 IMPALA-2 trial, the largest placebo-controlled study in autoimmune PAP, in which the DLCO improvement versus placebo was statistically significant at Week 24 1. The BLA was submitted in March 2025, received a Refusal to File in May 2025, was resubmitted in December 2025, and was formally filed with Priority Review in February 2026 12.
Segments
Market context
Autoimmune PAP is the most common form of PAP and a very small market, with a diagnosed prevalence estimated at six to seven cases per million people in the U.S. 1. No treatment is approved in the U.S. or Europe, and the current therapy is whole lung lavage, an invasive procedure 1. This creates an unmet need but a limited patient volume.
If MOLBREEVI is approved, commercial potential will depend on diagnosed patient numbers, reimbursement and adoption of a chronic treatment that the company expects to be long-term 1. Long-term data remain limited, which could influence uptake 1.
Trends
- U.S. regulatory processmixed
The initial refusal to file and the subsequent Priority Review show how sensitive the timeline is to FDA requirements on manufacturing comparability 12. If the FDA requests further information, the timeline could again be extended.
- Expansion into Europe and the UKtailwind
The EMA and MHRA have validated marketing applications, and the UK accelerated review assumes a 150-day assessment 2. This could open more markets if assessments progress.
- Dependence on external fundingheadwind
The company has raised capital through public offerings, private placements and loans, and losses continue 12. Manufacturing and launch preparation costs could rise with commercialization.
- Patent protection and exclusivitytailwind
The patent covering the drug-device combination runs through 2043, and a European patent on the liquid formulation protects until 2041 1. Orphan drug designations add market exclusivity after approval 1.
Competitive position
The company presents the absence of approved treatments as an advantage, but this does not rule out other therapies or off-label options 1. Injectable sargramostim is approved in Japan for autoimmune PAP, showing that an alternative already exists in another market 1.
The main competition is whole lung lavage, which remains the current standard, and any new candidates that could enter development 1. The company notes that no other candidate is in clinical development for autoimmune PAP in the U.S. or Europe, apart from MOLBREEVI 1.
- Whole lung lavage
Invasive procedure performed under general anesthesia, currently the standard therapy without an approved drug 1.
- Sargramostim (Leukine)
Injectable form of GM-CSF, approved in Japan for autoimmune PAP in April 2024 1.
- Other autoimmune PAP candidates in development
The company states that no other inhaled therapy is in clinical development for this disease in the U.S. or Europe 1.
- Investigator-sponsored inhaled GM-CSF studies
Open-label academic studies have reported promising results, indicating medical interest in the same drug class 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report11 Aug 2026
- Current report08 Jun 2026Departure or appointment of officers · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Quarterly report12 May 2026
- Proxy statement24 Apr 2026
- Current report13 Mar 2026Material agreement · Financial statements and exhibits
- Annual report13 Mar 2026
- Current report27 Jan 2026Material agreement · Creation of a direct financial obligation
- Current report09 Jan 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report12 Nov 2025
- Current report30 Oct 2025Material agreement · Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Savara Inc · 13 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Savara Inc · 11 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Savara Inc · 06 Aug 2020
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.